Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption
- Postato il 31 marzo 2026
- Di Google News
- 1 Visualizzazioni
Semarion secures $3.8 million to scale next-generation cell assay technology and accelerate pharma adoption
Semarion, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced it has raised $3.8 million USD (£2.9 million GBP).
